Literature DB >> 16500522

Sodium sensitivity of arterial blood pressure in L-NAME hypertensive but not eNOS knockout mice.

David L Mattson1, Carla J Meister.   

Abstract

The present studies determined the sensitivity of mean arterial pressure (MAP) to sodium intake in endothelial nitric oxide synthase (eNOS) knockout mice, wild-type mice (C56BL/6J), and wild-type mice intravenously administered the nonspecific NOS inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME, 8.6 mg/kg/d). Arterial blood pressure was measured from chronically implanted femoral arterial catheters in conscious, freely moving mice. The MAP was unaltered from the low sodium ( approximately 200 microEq/d) intake level of 106 +/- 3 mm Hg in wild-type mice when sodium intake was increased to approximately 1000 microEq/d (n = 12). Chronic administration of L-NAME to wild-type mice led to a sodium-dependent increase in MAP from 111 +/- 7 mm Hg to 124 +/- 5 mm Hg when the mice were placed on an elevated sodium intake (n = 7). In contrast to the L-NAME-treated mice, MAP was unaltered in eNOS knockout mice (n = 8) when sodium intake was increased (128 +/- 3 mm Hg v 129 +/- 5 mm Hg). These experiments demonstrate that eNOS knockout and L-NAME-treated wild-type mice are hypertensive relative to wild-type controls when sodium intake is elevated, but only L-NAME-treated mice exhibited a sodium-sensitive increase in MAP. Therefore, nitric oxide produced by eNOS does not appear to be important in the physiologic adaptation to elevated sodium chloride intake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500522     DOI: 10.1016/j.amjhyper.2005.09.012

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

1.  Pendrin protein abundance in the kidney is regulated by nitric oxide and cAMP.

Authors:  Monika Thumova; Vladimir Pech; Otto Froehlich; Diana Agazatian; Xiaonan Wang; Jill W Verlander; Young Hee Kim; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-18

2.  Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin.

Authors:  Jill W Verlander; Seongun Hong; Vladimir Pech; James L Bailey; Diana Agazatian; Sharon W Matthews; Thomas M Coffman; Thu Le; Tadashi Inagami; Florence M Whitehill; I David Weiner; Donna B Farley; Young Hee Kim; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

3.  High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity.

Authors:  Libor Kopkan; Arthur Hess; Zuzana Husková; Ludek Cervenka; L Gabriel Navar; Dewan S A Majid
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-07

4.  Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice.

Authors:  Luminita H Pojoga; Tham M Yao; Sumi Sinha; Reagan L Ross; Jeffery C Lin; Joseph D Raffetto; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733

5.  Renal medullary ETB receptors produce diuresis and natriuresis via NOS1.

Authors:  Daisuke Nakano; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2008-02-27

6.  Endothelial Cullin3 Mutation Impairs Nitric Oxide-Mediated Vasodilation and Promotes Salt-Induced Hypertension.

Authors:  Jing Wu; Shi Fang; Ko-Ting Lu; Gaurav Kumar; John J Reho; Daniel T Brozoski; Adokole J Otanwa; Chunyan Hu; Anand R Nair; Kelsey K Wackman; Larry N Agbor; Justin L Grobe; Curt D Sigmund
Journal:  Function (Oxf)       Date:  2022-04-08

7.  Increased NOS coupling by the metabolite tetrahydrobiopterin (BH4) reduces preeclampsia/IUGR consequences.

Authors:  Laurent Chatre; Aurélien Ducat; Frank T Spradley; Ana C Palei; Christiane Chéreau; Betty Couderc; Kamryn C Thomas; Anna R Wilson; Lorena M Amaral; Irène Gaillard; Céline Méhats; Isabelle Lagoutte; Sébastien Jacques; Francisco Miralles; Frédéric Batteux; Joey P Granger; Miria Ricchetti; Daniel Vaiman
Journal:  Redox Biol       Date:  2022-07-30       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.